Gwen A. Fyfe, Director at Cascadian Therapeutics, Inc. (CASC), bought 1,666 shares at $4.12 ($7K) on 2017-03-28, disclosed to the SEC on 2017-03-30.
Open-market purchase of $7k CASC by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.